2005
10th European AIDS Conference/EACS, Dublin, November 2005
Posters
1 Liver-related Deaths among HIV-infected Persons; Data from the D:A:D Study. R Weber, N Friis-Møller, CA Sabin, P Reiss, A D’Arminio Monforte, F Dabis, W El-Sadr, S De Wit, L Morfeldt, MG Law, C Pradier, G Calvo, O Kirk, AN Phillips, JD Lundgren on behalf of the D:A:D study group.
Poster PE18.4/7
2 Comparison of resistance profiles between patients starting nevirapine and efavirenz in EuroSIDA. W Bannister, L Ruiz, B Ledergerber, A Cozzi-Lepri, O Kirk, S Staszewski, C Loveday, B Clotet, A Phillips, J Lundgren for the EuroSIDA study group. Poster PE17.5/2
3 Evolution of drug resistance in HIV infected patients remaining on a virologically failing cART regimen. A Cozzi-Lepri, AN Phillips, L Ruiz, B Clotet, C Loveday, J Kjaer, N Clumeck, L Viksna, F Antunes, L Machala and JD Lundgren. Poster PE17.4/2
4 Pilot of the CoDe (Coding of Death) project - a standardized approach to code causes of death in HIV infected individuals. CH Olsen, N Friis-Møller, A d'Arminio Monforte, G Chene, R Davey, S De Wit, F De Wolf, M Egger, M Ellefson,W El-Sadr, O Kirk, M Law, B Ledergerber, C Lewden, S Mateu, A Mocroft, T Peto, A Phillips, C Pradier, P Reiss, F Rhame, C Sabin, J Sterne, R Weber, B Åkerlund, JD Lundgren, for the CoDe Working Group. Poster PE18.4/9
Oral presentations
1 Use of antimycotic therapy is an independent risk factor for HIV-disease progression among patients with a CD4 count above 200/µL in the era of combination antiretroviral therapy . D Podlekareva, A Mocroft, P Reiss, P Aldins, C Katlama, B Ledergerber, HJ Stellbrink, AD Monforte, O Kirk, JD Lundgren Abstract PS 2/1
2 Is there an association between the endpoints in trials of virological efficacy and clinical long-term prognosis? O Kirk, A Mocroft, P Reiss, B Ledergerber, B Knysz, G Fätkenheuer, S Chaplinskas, JM Gatell, A Phillips, JD Lundgren for the EuroSIDA Study Group Abstract PS 3/4
3 Clinical progression according to HIV drug resistance accumulated on antiretroviral therapy in EuroSIDA. A Cozzi-Lepri, A Phillips, A Mocroft, O Kirk, L Ruiz and JD Lundgren. Abstract PS 6/4
4 Is there evidence for an increase in the death rate from liver-related diseade in patients with HIV? The EuroSIDA study. JD Lundgren, A Mocroft, V Soriano, J ROchstroh, P Reiss, O Kirk, S de Wit, JM Gatell, B Clotet, A Phillips Abstract PS 7/2
3rd IAS Conference on HIV Pathogensis and Treatment, Rio de Janeiro, July 2005
1 Rates of viral suppression and regimen change according to initial HAAR regimen. A collaborative analysis of 12 prospective cohort studies. R Hogg, J Lundgren, D Costagliola, A d´Arminio Monforte, B Ledergerber, F de Wolf, G Fusco, S Staszewski, G Chene, A Phillips, J Gil, N Schmeisser, M May, J Sterne, M Egger.
2 Impact of Lamivudine (3TC) on the risk of liver related death (LRD) in 2,041 HBsAg and HIV-positive inidividuals. Results of an intercohort analysis. M Puoti, A Cozzi-Lepri, G Parainfo, J Lundgren, M Rickenback, I Suarez-Lozano, M Winnock, A Gervais, J Gill, J Rockstroh, C Mussini, A Castagna, A De Luca, A d´Arminio Monforte.
3 Risk factors for new onset diabetes mellitus (DM) in HIV patients. C Sabin, N Friis-Møller, P Reiss, R Weber, A d´Arminio Monforte, F Dabis, W El-Sadr, S de Wit, S Mateu, O Kirk, C Pradier, L Morfeldt, M Law, J Lundgren.
3rd European Resistance Conference, Athens, March 2005
1 The COLATE trial: comparison of the evolutionary distance for protease and reverse transcriptase sequences. J Kjær Poster(352 KB) abstract
2 How to read viral load in patients with virus variants that you can not suppress.
J Lundgren
12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005
1 Cardiovascular outcomes in HIV infection. JD Lundgren et al
2 Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study. C Sabin, L Morfeldt, N Friis-Møller, M Rickenbach, P Reiss, A D´Arminio Monforte, C Pradier, O Kirk, G Calvo, M Law, P Mercié, W El-Sadr, S De Wit, JD Lundgren on behalf of the D:A:D study group. Poster # 866(70 KB)
3 Relationship between prolonges exposure to combination antiretroviral therapy (cART) and myocardial infarction (MI): effect of sex, age and lipid changes. W El-Sadr, P Reiss, S De Wit, A D´Armino Monforte, R Thiebaut, L Morfeldt, R Weber, C Pradier, G Calvo, MG Law, O Kirk, C Sabin, N Friis-Møller JD Lundgren on behalf of the D:A:D study group.
4 HIV and Non-HIV-related deaths and their relationship to immunodeficiency; the D:A:D study. R Weber, N Friis-Møller, C Sabin, P Reiss, A D´Arminio Monforte, F Dabis, W El-Sadr, S De Wit, L Morfeldt, MG Law, C Pradier, G Calvo, C Holkmann Olsen, AN Phillips, JD Lundgren on behalf of the D:A:D study group. Poster #595 (75 KB)
5 Risk of AIDS and death at given HIV-RNA and CD4 count level, according to specific antiretroviral drugs in the CART regimen. C Holkmann-Olsen1, J Gatell, B Ledergerber, C Katlama, N Friis-Møller, J Weber, A Horban, S Staszewski, J Lundgren, A Phillips, and EuroSIDA
Poster #601(78 KB)
6 HIV-1 subtypes and virological response to HAART in Europe. W Bannister, L Ruiz, C Loveday, S Vella, K Zilmer, D Podlekareva, B Knysz, A Phillips, J Lundgren, A Mocroft and the EuroSIDA study group Poster #598(157 KB)
7 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on virological response to therapy. A Cozzi-Lepri, L Ruiz, C Loveday, A Phillips, B Clotet, P Reiss, J Lundgren, and EuroSIDA Study Group Poster #708(113 KB)
8 A Comparison of Risk of Treatment Limiting Adverse Events in HCV-co-infected vs Non-co-infected persons with HIV in EuroSIDA. JD Lundgren, J Rockstroh, V Soriano, B Ledergerber, O Kirk, E Vinogradova, P Reiss, C Katlama, A Blaxhult, A Mocroft, and EuroSIDA Study Group
Poster #946(137 KB)
9 Mortality Rates According to Initial HAART Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies. R Hogg, J Lundgren, D Costagliola, A Monforte, B Ledergerber, F de Wolf, G Fusco, S Staszewski, G Chêne, A Phillips, J Gill, J Rockstroh, M May, J Sterne, M Egger, and ART Cohort Collaboration
2004
11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004
1 Predictors of Hypertension and Changes in Blood Pressure in HIV-infected Patients in the D:A:D study. R Thiebaut, W El-Sadr, N Friis-Møller, M Rickenbach, P Reiss, A D´Arminio Monforte, L Morfeldt, C Pardier, O Kirk, S De Wit, G Calvo, M Law, C Sabin, J D Lundgren and D:A:D Study Group. (DAD 75)
2 Final Week 48 Analysis of a Phase 4, Randomised, Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Continued Lamivudine Twice Daily Versus Discontinuation of Lamivudine in HIV-1-infected Adults with Virological Failure on ongoing Combination Treatments Containing Lamivudine: The COLATE Trial. U Dragsted, Z Fox, L Mathiesen, C Katlama, M Youle, J Gerstoft, J N Bruun and J D Lundgren for the COLATE Trial Group (COLATE 549)
3 Time to Triple Drug Class Failure after Initiation of HAART. A Mocroft, B Ledergerber, J P Viard, S Staszewski, M Murphy, A Chiesi, A Horban, A B Hansen, A N Phillps, J D Lundgren and the EuroSIDA Study Group. (EuroSIDA 554)
4 The Role of Genetic Polymorphisms of the MDR1 Gene in the MaxCmin1 Study. A Owen, Z Fox, L Almond, U Bak Dragsted, D Back, M Youle, J Lundgren, S Khoo, and the MaxCmin1 Steering Commitee. (MaxCmin1 619b)
5 Lipid Profiles of Patients Enrolled in the MaxCmin2 Trial: A Randomised, Open-label Multi-centre Comparative Trial Evaluating the Safety and Efficacy of Lopinavir/ Ritonavir (400/100 mg twice daily) vs Saquinavir/Ritonavir SQV/r (1000/100 mg twice daily). S L Walmsley, J Benetucci, A Brutus, N Clumeck, U B Dragsted, B Gazzard, N Obel, P Vernazza, Z Fox, J D Lundgren and on behalf of the MaxCmin2 Trial Group. (MaxCmin2 720)
6 Cardio- and Cerebrovascular Events and Predicted Rates of Myocardial Infarction in the D:A:D study. M G Law, A D´Arminio Monforte, N Friis-Møller, R Weber, W El-Sadr, P Reiss, F Dabis, L Morfledt, S De Wit, C Pradier, G Calvo, O Kirk, C Sabin, A N Phillips and JD Lundgren. (DAD 737)
7 Hepatitis B and Hepatitis C in the EuroSIDA Cohort: Prevalence and Effect on Mortality, AIDS Progression and Response to HAART. J Rockstroh, D Konopnicki, V Soriano, O Kirk, F Antunes, B Knysz, C Tural, S De Wit, A Mocroft, J Lundgren and the EuroSIDA Study Group.
(EuroSIDA 799)
XV International AIDS Conference, July 2004, Bangkok
1 Estimation of clinical events in the control arm of the ESPRIT trial based on data from an observational database. J D Lundgren
(ESPRIT B10257) abstract
2 Predictors of the CD4 count response during the first 8 months of follow-up in the IL-2 arm of ESPRIT. K Ruxrungtham, Z V Fox, F Antunes, J D Bebchuk, R T Davey, B Gazzard, N G Klimas, A M Labriola, M H Losso, J D Neaton, S Staszewski, L Weiss, A N Phillips, J D Lundgren.
(ESPRIT WeOrB1288) abstract
3 Comparison of observed clinical event rates in the ESPRIT trial with projections from the EuroSIDA study. J D Lundgren, A Mocroft, J Bebchuck, S. Staszewski, F Antunes, B Knysz, M Law, A N Phillips, J Neaton.
(ESPRIT/EuroSIDA WePeB5685) abstract
44th ICAAC, October 2004, Washington
1 Comparison of 6 HIV-1 genotypic resistance algorithms for predicting viral load change to week 4. Z Fox, J Gerstoft, UB Dragsted, AN Phillips, P Cahn, J Gatell, JD Lundgren (MaxCmin2 H-185)
6th International Conference on Adverse Drug Reactions and Lipodystrophy in HIV, October 2004, Washington
1 Association of risk toxicity with drug levels of saquinavir boosted with ritonavir in the MaxCmin 1 & 2 trials. JD Lundgren, Z Fox, US Justesen, S Warmsley, M Youle, P Vernazza, J Gerstoft, M Losso, and UB Dragsted on behalf of the MaxCmin trial groups. (MaxCmin 1&2 79)
2 Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen. A Mocroft, AN Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, JD Lundgren for the EuroSIDA study group. (EuroSIDA 74)
7th International Congress on Drug Therapy in HIV Infection, November 2004 Glasgow
1 Interruption/stopping HAART and risk of clinical disease progression to AIDS/death in EuroSIDA. C Holkmann-Olsen, A Mocroft, S Vella, A Blaxhult, N Clumeck, O Kirk, M Fisher, C Katlama, A Phillips, J Lundgren (EuroSIDA P5) abstract
2 What is the status of IL-2? J D Lundgren. (PL8.1)
3 Why do patients stop antiretrovirals used as part of an initial HAART regimen? Results from the EuroSIDA study group. A Mocroft, A Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, J Lundgren (EuroSIDA PL14.1)
4 HIV-patients across Europe: regional differences in patient characteristics. D Podlekareva, W Bannister, L Viksna, A Mocroft, B Knysz, P Reiss, N Chentsova, D Duiculescu, JD Lundgren, O Kirk, The EuroSIDA Study. (EuroSIDA P67)
2003
10th Conference on Retroviruses and Opportunistic Infections, Boston, February 2003
1. Exposure to HAART is associated with an increased risk of myocardial infarction: The DAD study. N Friis-Møller, R Weber, A D´Arminio Monforte, W El-Sadr, P Reiss, F Dabis, L Morfeldt, S De Wit, C Pradier, G Calvo, M Law, O Kirk, C Sabin, JD Lundgren. (DAD 130)
2. Factors affecting CD4 count slope in patients with stable viral load following three class virologic failure: The PLATO collaboration. B Ledergerber, JD Lundgren, G Fusco, R Weber, F Wit, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A D´Armenio Monforte, C Mussioni, F Lampe, MJ Gill, A Phillips. (PLATO 146lb)
3. Changes in AIDS, death Rates and survival after AIDS in the EuroSIDA study: 1994-2002. A Mocroft, B Ledergerber, C Katlama, O Kirk, P Reiss, A D´Arminio-Monforte, B Knysz, M Dietrich, AN Phillips, JD Lundgren. (EuroSIDA 180)
4. Does it matter where you came from? Prognosis of patients starting potent therapy, according to initial response. JAC. Sterne, M May, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf, J Lundgren, JS Fusco, S Staszewski, F Raffi, RS Hogg, AN Phillips, MJ Gill, G Faetkenheuer, G Chene. (Art Cohort 181)
5. The changing incidence of clinical AIDS events in 12,574 treatment-naïve patients starting HAART. C Sabin, A D´Arminio Monforte, M May, S Grabar, P Reiss, J Lundgren, A Justice, S Staszewski, C Leport, F Dabis, JSG Montaner, M Johnson, J Gill, G Faetkenheuer, M Egger. (Art Cohort 569)
British HIV Association Conference, Manchester, April 2003
1. ART and myocardial infarction: how to deal with the incertainty. JD Lundgren
2nd International AIDS Society Conference, Paris, July 2003
1. Factors contributing to the success of ART following three class virological failure: The PLATO collaboration.B Ledergerber, JD Lundgren, GP Fusco, R Weber, F Wit, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A d´Arminio Monforte, C Mussini, F Lampe, MJ Gill and AN Phillips. (Plato 576)
2. Presence of GB virus C and response to HAART, analysed within the MaxCmin1 trial comparing the efficacy and safety of indinavir/ritonavir versus saquinavir/ritonavir. HL Tilmann, T Kaiser, Z Fox, S Staszewski, F Antunes, A d´Arminio Monforte, A Telenti, UB Dragsted and JD Lundgren on behalf of the MaxCmin Trial Group. (MaxCmin 1006)
3. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): The MaxCmin2 trial. M Youle, J Gerstoft, Z Fox, M Losso, DT Jayweera, A Rieger, JN Bruun, A Castagna, S Walmsley, A Hill, UB Dragsted and JD Lundgren for the MaxCmin2 Trial Group.
(MaxCmin2 LB23)
5th International Conference on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, July 2003.
1. Safety on NNRTI therapy. Data from the EuroSIDA study. N Friis-Møller, O Kirk, P Reiss, A Mocroft, C Katlama, A Horban, D Banhegyi, J Gatell, B Clotet, AN Phillips and JD Lundgren for the EuroSIDA Study Group. (EuroSIDA 24)
2. Hepatotoxicity of ritonavir-boosted indinavir (IDV/r 800/100 mg twice daily) and saquinavir (SAQ/r 1000/100 mg twice daily) in a phase IV, randomised, open-label and multi centre trial in adult HIV-1 infection: MaxCmin1 trial. JD Lundgren, A Hill, Z Fox, N Clumeck, JN Bruun, J Bennetucci, I Cassetti, P Vernazza, A Rieger and UB Dragsted on behalf of the MaxCmin1 trial. (MaxCmin1 126)
43nd ICAAC, Chicago, September 2003
1. Risk of death following triple class virological failure: The PLATO Collaboration. JD Lundgren, B Ledergerber, GP Fusco, R Weber, P Reiss, F Castelli, S Staszewski, R Hogg, AS Walker, K Petoumenos, A D´Arminio Monforte, C Mussini, F Lampe, MJ Gill, AN Phillips.
9th EACS, Warsaw, October 2003
1. Pharmacokinetics from a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial. U Justesen, Z Fox, C Pedersen, P Cahn, J Gerstoft, N Clumeck, A Duran, B Peters, N Obel, A Castagna, U Dragsted, J Lundgren on behalf of the MaxCmin1 trial group. (MaxCmin 1 F2/5)
2. Virologic outcome of patients with virologic failure who start a regimen containing Abacavir: EuroSIDA Study. C Cabrera, A Cozzi-Lepri, AN Phillips, C Loveday, T Puig, O Kirk, M Ait-Khaled, B Ledergerber, J Lundgren, B Clotet, L Ruiz. (EuroSIDA F6/5)
3. Prevalence of lipodystrophy and retinoid syndrome in a 48-week randomised trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial. S De Wit, H Wand, M Law, A Castagna, JN Bruun, M Youle, P Vernazza, I Cassetti, J Benetucci, U Dragsted, JD Lundgren on behalf of the MaxCmin1 trial group. (MaxCmin 1 F8/2)
4. Hepatitis B (HBV) in the EuroSIDA Cohort: prevalence and impact on mortality, AIDS progression and response to HAART. D Konopnicki, S De Wit, F Antunes, B Ledergerber, C Katlama, K Zilmer, O Kirk, S Vella, A Mocroft and JD Lundgren for the EuroSIDA Group.
(EuroSIDA F9/3)
5. Changing incidence of central nervous system (CNS) AIDS-related diseases in the EuroSIDA cohort. A d'Arminio Monforte, P Cinque, A Mocroft, FD Goebel, F Antunes, C Katlama, US Justesen, S Vella, O Kirk, JD Lundgren for the EuroSida Study Group. (EuroSIDA F9/6)
6. Changes in hospital admissions across Europe in 1995-2002. A D’Arminio Monforte, A Mocroft, O Kirk, MA Johnson, N Friis-Moller, D Banhegyi, A Blaxhult, F Mulcahy, JM Gatell, JD Lundgren for the EuroSIDA study group. (EuroSIDA F9/7)
7. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): The MaxCmin2 trial. M Youle, J Gerstoft, Z Fox, M Losso, DT Jayweera, A Rieger, JN Bruun, A Castagna, S Walmsley, A Hill, UB Dragsted, JD Lundgren for the MaxCmin2 trial group. (MaxCmin2 F11/3)
8. Influence of Hepatitis C coinfection on HIV disease progression within the EuroSIDA Cohort. J Rockstroh, A Mocroft, V Soriano, C Tural, M Losso, P Reiss, L Machala, O Kirk, B Ledergerber, JD Lundgren for the EuroSIDA study group. (EuroSIDA F12/4)
9. Regional differences in characteristics of HIV-patients from across Europe The EuroSIDA study. LViksna, A Mocroft, B Knysz, JP Viard, M Dietrich, D Duiculescu, A Blaxhult, F Antunes, JD Lundgren, O Kirk for the EuroSIDA Study Group. (EuroSIDA 18.2/2)
10. Use of and response to antiretroviral therapy in regions of Europe The EuroSIDA Study. A Horban, A Mocroft, B Ledergerber, A Johnson, S Chaplinskas, JM Gatell, A Chiesi, AN Phillips, JD Lundgren, O Kirk for the EuroSIDA study group. (EuroSIDA 18.2/3)
2002
9th Conference on Retroviruses and opportunistic Infections in Seattle, February 2002
1. Interruption/Stopping Antiretroviral Therapy and the Risk of Clinical Diseases: Results from the EuroSIDA Study. JD Lundgren, S Vella, L Paddam, A Blaxhult, N Vetter, N Clumeck, G Panos, M Fisher, C Katlama, and AN Phillips. (EuroSIDA 48)
2. Safe Interruption of Maintenance Therapy (MT) against Prior Infection with 4 Common HIV-Associated Opportunistic Pathogens during Highly Active Antiretroviral Therapy. O Kirk, P Reiss, C Uberti-Foppa, M Bickel, J Gerstoft, C Pradier, F Wit, B Ledergerber, JD Lundgren, and H Furrer for 7 European HIV cohorts. (EuroSIDA 37)
3. Analysis of Virological Efficacy in Randomised Trials of Antiretroviral Regimens: Drawbacks of No HIV-RNA Measurements after Premature Interruption of Therapy. O Kirk, M Law, C Pedersen. RM Gulick, G Moyle, AN Phillips, and JD Lundgren. (EuroSIDA Abstract G104e, Poster 551-T)
4. Distinguishable Lipid Profiles between PI and NNRTI Therapy May Carry Different Risk of CardiovascularDisease (CVD). F van Leth, N Friis-Møller, R Weber, A d'Arminio Monforte, O Kirk, R Thiebaut, L Morfeldt, C Pradier, G Calvo, M Law, G Bartsch, S De Wit, C Sabin, JD Lundgren, P Reiss for the D:A:D Study Group. (DAD 34)
5. The Interim Analysis of a Phase IV Randomised, Open-Label, Multicentre Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg bid) vs. Saquinavir/Ritonavir (1000/100 mg bid) in Adult HIV-1 Infection: The MaxCmin1 Trial. A Castagna, UB Dragsted, J-P Chave, A Rieger, G Carosi, S van der Geest, H Nielsen, and JD Lundgren on behalf of the MaxCmin1 trial group.
(MaxCmin G1008e)
British HIV Association Conference, York, April 2002
1. Current status of patients starting HAART during 1996: descriptive analysis of EuroSIDA participants. Lucy Paddam, O Kirk, JM Gatell, P Reiss, F Antunes, AM Johnson, A Horban, C Pradier, B Ledergerber, AN Phillips, and JD Lundgren on behalf of The EuroSIDA Study Group.
(EuroSIDA)
The 14th International AIDS Conference, Barcelona, July 2002
1. Modelling Risk of Cardiovascular Events in HIV. M Law, N. Friis-Møller, R Weber, P Reiss, A d'Arminio Monforte, O Kirk, R Thiebaut, C Pradier, L Morfeldt, G Calvo, G Bartsch, S De Witt, C Sabin, JD Lundgren for the D:A:D Study Group. (DAD WePeC6260)
2. Virological, immunological and clinical response to highly active antiretroviral therapy: the gender issue revisited. AL Moore, O Kirk, JD Lundgren, AN Phillips (EuroSIDA B10508)
3. Week 48 data of a randomised trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection. P Cahn, UB Dragsted, C Pedersen, B Peters, A Duran, N Obel, JM Gatell, C Leen, J v Lunzen, A Stoehr, J Lederman, and JD Lundgren on behalf of the MaxCmin1 trial group. (MaxCmin WeOrB1265)
4. A randomised trial comparing HAART regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in PI and NNRTI naïve patients. O Kirk, JD Lundgren, C Pedersen, L Mathiesen, H Nielsen, T Katzenstein, N Obel, J Gerstoft. (DAPIS TuOrB1188)
5. What is the prognostic value of baseline CD4 cell count and viral load six months after initiating potent antiretroviral therapy? ART Cohort Collaboration. JAC Sterne, S Grabar, A d’Arminio Monforte, M Rickenbach, F de Wolf, JD Lundgren, J Fusco, V Miller, F Raffi, F Dabis, RS Hogg, F Lampe, MJ Gill, B salzberger, M May, M Egger. (ART Cohort C10680)
6. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration. G Chene, M May, D Costagliola, A d’Arminio Monforte, C Junghans, F de Wolf, JD Lundgren, G Fusco, V Miller, C Leport, F Dabis, RS Hogg, AN Phillips, MH Gill, B Salzberger, JAC Sterne, M Egger. (ART Cohort TuOrB1140)
7. Construction and validation of a prognostic model for progression to AIDS or death in drug-naïve patients starting potent antiretroviral therapy ART Cohort Collaboration. M May, JAC Sterne, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf, JD Lundgren, AC Justice, V Miller, G Chene, F Cabid, RS Hogg, C Sabin, MJ Gill, B Salzberger, M Egger. (ART Cohort TuPeB4668)
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, December 2002
1. Final Analysis of a Randomised Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir versus Saquinavir/Ritonavir in Adult HIV-1 Infection: The MaxCmin1 Trial. J Gerstoft, UB Dragsted, P Cahn, A Castagna, A Duran, A Hill, C Pedersen, B Peters, P Vernazza, M Youle, and JD Lundgren on behalf of the MaxCmin1 trial group. (MaxCmin ICAAC02-A-2853-ASM)
2. Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in Antiretroviral Naïve HIV Patients. J Gerstoft, O Kirk, N Obel, H Nielsen, L Mathiesen, C Pedersen, J Lundgren.
3. The Evolution of HIV in Patients with Insufficient Viral Suppression during HAART. TB Kristiansen, AG Pedersen, J Eugen-Olsen, T Katzenstein, JD Lundgren.
6th Congress on Drug Therapy in HIV Infection, Glasgow, November 2002
1. Lipid profiles on therapy with PI. The D:A:D Study. C Pradier, C Sabin, N Friis-Møller, R Weber, P Reiss, A d'Arminio Monforte, O Kirk, R Thiebaut, E Fontas, L Morfeldt , G Calvo, M Law, G Bartsch, S De Witt, JD Lundgren for the DAD Study Group. (DAD PL21.1)
2. Virological rebound after suppression on HAART: result from the EuroSIDA study. A Mocroft, A Phillips, P Reiss, B Clotet, B Ledergerber, J Gatell, C Katlama, S Vella, N Clumeck, JD Lundgren (EuroSIDA PL5.4)
3. The interim analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of Lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin2 trial. UB Dragsted, J Gerstoft, M Youle, A Duran, DT Jayaweera, A Rieger, JN Bruun, A Castagna, S Walmsley, Z Fox, A Hill, and JD Lundgren for the MaxCmin2 trial group. (MaxCmin2 PL14.5)
4. Final Safety and Efficacy Analysis of a Randomised Trial Evaluating Indinavir/Ritonavir versus Saquinavir/Ritonavir in Adult HIV-1 Infection: The MaxCmin1 Trial. J Gerstoft, U Bak Dragsted, P Cahn, A Castagna, A Duran, A Hill, C Pedersen, B Peters, P Vernazza, M Youle, and JD Lundgren on behalf of the MaxCmin1 trial group. (MaxCmin P29)
4th European Conference on the Methods and Results of Social and Behavioural Research on AIDS, September 2002, Vilnius.
1. The EuroSIDA Study 1994-2002. O Kirk, on behalf of the EuroSIDA study Group.
2001
The Australian ASHM Conference, Melbourne, 2001
1. Cardiovascluar risk in Hiv patients - association with antiretroviral therapy. The DAD Study. M Law, N Friis-møller, P Reiss, A d´Arminio Monforte, M Rickenbach, R Thiebaut, C Pradier, L Morfeldt, G Calvo, G Bartsch, S De Wit, AN Phillips, JD Lundgren for the DAD study group.
8th Conference on retroviruses and opportunistic infections, Chicago, February 2001
1. Changes in cause of death across Europe. A Mocroft, R Brettle, O Kirk, A Blaxhult, JM Parkin, F Antunes, P Francioli, A d´Arminio Monforte, AN Phillips, and JD Lundgren. (EuroSIDA 298)
2. Virological and clinical outcome of NNRTI-containing regimens for 1932 patients in EuroSIDA. AN Phillips, C Pradier, A Lazzarin, B Clotet, F Goebel, P Hermans, F Antunes, B Ledergerber, O Kirk, and J Lundgren. (EuroSIDA 324)
5th International Workshop on HIV observational databases, Monte Carlo, April 2001
1. The influence of the analytic method used in clinical trial of HAART. Results form EuroSida and randomised clinical trials (RCT). O Kirk and J Lundgren. (EuroSIDA oral ses. 2)
2. Predictors of clinical outcome – how different are they form predictors of virological outcome? JD Lundgren (EuroSIDA oral ses 3)
3. The DAD-study: Data collection on adverse events of anti-HIV drugs. DAD study group (DAD oral ses.6)
4. Changes in viral load in people with virological failure who remain on the same HAART regimen. A Cozzi-Lepri, A Phillips, V Miller, J Lundgren. (EuroSIDA oral ses. 4)
5. Design of safety reports from the EuroSIDA study. N Friis-Møller, O Kirk, JD Lundgren. (EuroSIDA poster ses.6)
The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001
1. Non-Hodgkin lymphoma (NHL) among HIV-infected patients in the era of highly active antiretroviral therapy (HAART). O Kirk, A Mocroft, S Barton, C Pedersen, P Skinhøj, V Miller, J Lundgren. (EuroSIDA 69)
2. Soluble urokinase plasminogen activator receptor (suPAR) – A potential marker for responsiveness to HAART? K Jensen, C Madsen, O Kirk, A Meyer, J Parner, J Lundgren, K Krogsgaard, J Eugen-Olsen. (Diverse 281)
8th European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, October 2001.
1. A randomised trial comparing continued indinavir vs switching to indinavir plus retonavir in HIV-patients having suppressed viral load with indinavir plus two nucleoside analogue reverse transcriptase inhibitors: The BEST study. J Gerstoft, J Mallolas, J Lundgren, G Faetkenheuer, A D´Arminio Monforte, F Antunes, P Reiss, JM Gatell. (BEST 240)
2. A phase IV randomised open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) vs. saquinavir /ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin1 trial. UB Dragsted. (MaxCmin1 407)
3. Factors affecting incidence of and survival after CMV end-organ disease in patients with AIDS in Europe. I Yust, P Reiss, D Turner, O Kirk, C Katlama, A Mocroft, J van Lunzen, M Burke, A Chiesi, JD Lundgren. (EuroSIDA 521)
4. Cardiovascular risk-factors in HIV patients - association with antiretroviral therapy. The DAD Study. N Friis-Møller, P Reiss, O Kirk, A D'Arminio Monforte, M Rickenbach, R Thiebaut, C Pradier, L Morfeldt, G Calvo, M Law, G Bartsch, S De Witt, AN Phillips, JD Lundgren for the DAD Study Group. (DAD 408)
41st Interscience Conference on Antimicrobial agents and Chemotherapy, Chicago, December 2001.
1. Risks for cardiovascular disease (CVD) associated with antiretroviral therapy (ART). R Weber, N Friis-Møller, F Dabis, P Reiss, A D´Armino Monforte, G Calvo, C Pradier, L Morfeldt, M Law, A Phillips, JD Lundgren. (DAD I-1326)
2. The DAD study: Data collection on adverse events of anti-HIV drugs. The DAD Study group (Oral pres. ses. 6)
3. The Stability of the viral load in subjects with virological failure who remain on the same HAART regimen: The EuroSIDA study. JD Lundgren, A Cozzi-Lepri, V Miller, B Ledergerber, S Vella, J Weber, JN Bruun, O Kirk, B Clotet, A. Phillips. (EuroSIDA I-1915)
2000
7th Conference on retroviruses and opportunistic infections, San Francisco Jan/Feb 2000
1. Association of viral load, CD4 cell count, and treatment with clinical progression in HIV-patients with very low CD4 cell counts: The EuroSIDA cohort. V Miller, A Mocroft, B Clotet, B Ledergerber, O Kirk, A D´Arminio Monforte, and J Lundgren. (EuroSIDA 454) abstract
2. Virological response to a second-line protease inhibitor (PI) regimen: Laboratory markers and choice of treatment. A Mocroft, AN Phillips, V Miller, J Gatell, J Van Lunzen, A Lazzarin and J Lundgren. (EuroSIDA 539)
3. EuroSIDA: Temporal Changes in response to HAART. JD Lundgren, O Kirk, G Panos, FD Goebel, A Blaxhult, AN Phillips, A Mocroft.
(EuroSIDA 757)
4. It is safe to discontinue secondary prophylaxis for PCP in HIV-infected patients with HAART: Results from eight prospective European cohorts. B Ledergerber, A Mocroft, P Reiss, HJ Furrer, O Kirk, V Miller, C Pradier, C Uberti-Foppa, A D´Arminio-Monforte, MM Schneider and JD Lundgren. (EuroSIDA LB5)
The XIII International AIDS Conference, Duban, July 2000.
1. Low body weight and type of protease inhibitor (PI) predict treatment-limiting adverse drug reactions (TLADR) among HIV-infected patients starting a PI regimen. O Kirk, J Gerstoft, C Pedersen, H Nielsen, N Obel, TL Katzenstein, L Mathiesen, JD Lundgren. (Protease WePeB4283) abstract
2. The influence of Hepatitis C virus (HCV) on the prognosis of HIV-infected persons: The EuroSIDA study. V Soriano, O Kirk, F Antunes, M Johnson, A d´Arminio-Monforte, LS Teglbjorg, F-D Goebel, JD Lundgren.
(EuroSIDA ThOrB655)
3. Factors associated with starting HAART and pneumocytis carinii pneumonia (PCP) prophylaxis among HIV seroconverters enrolled in the EuroSIDA study. P Vanhems, O Kirk, A Mocroft.
(EuroSIDA TuPeC3372)
40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 2000.
1. Ykl-40 is elevated in cerebrospinal fluid from patients with bacterial meningitis and is associated with outcome. C Østergaard, JS Sørensen, T Benfield, PA Price, JD Lundgren. (Diverse 428) abstract
2. Clinical correlation of pneumocystis carinii internal transcribed spacer genotypes in AIDS- related P. carinii Pneumonia. J Helweg-Larsen, C Lee, S Jin, Y Hsueh, T Benfield, J Hansen, JD Lundgren, B Lundgren.
(Diverse 1318)
3. The change in risk of clinical progression after initiation of HAART: The EuroSIDA study. JD Lundgren, A Mocroft, JM Gatell, O Kirk, C Katlama, S Vella, ANPhillips. ( EuroSIDA 1905)
Fifth International Congress on Drug Therapy in HIV-infection, Glasgow, October 2000.
1. Viral load changed in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load. AN Phillips, S Staszewski, R Weber, O Kirk, P Francioli, V Miller, P Vernazza, J Lundgren and B Ledergerber. (EuroSIDA PL3.4) abstract
2. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. S Jensen-Fangel, O Kirk, A Blaxhult, J Gerstoft, C Pedersen, FT Black, JD Lundgren and N Obel. (EuroSIDA P69) abstract
3. The effect of HAART on retinal and extraocular cytomegalovirus infection in patients with AIDS in Europe. I Yust, A Mocroft, D Turner, C Katlama, B Clotet, O Kirk, J Van Lunzen, P Reiss, M Burke, A Chiesi, J Lundgren.
(EuroSIDA P375)
4. Decreasing incidence of non-Hodgkin Lymphoma (NHL) in the era of HAART: The EuroSIDA Study. O Kirk, A Mocroft, F Antunes, C Pedersen, P Skinhøj, V Miller, A Lazzarin, JM Gatell, S Barton and JD Lundgren.
(EuroSIDA P404)
5. Admission to hospital in the HAART era: The EuroSIDA study. N Friis-Møller, O Kirk, A Mocroft, JN Bruun, A Johnson, R Colebunders, R Proenca, J Gonzalés-Lahoz, A D´Arminio Monforte and JD Lundgren.
(EuroSIDA P410)